Antidiabetic Medications and Bone Fragility Research Insights - Careggi Hospital
Delve into the correlation between antidiabetic medications and bone fragility through a comprehensive study led by Ilaria Dicembrini at the Diabetology Department of Careggi Hospital. Explore the impact of GLP-1 & Therapeutic application, SGLT-2i drugs like canagliflozin and dapagliflozin on bone health. Uncover the FDA warnings, clinical trial data, and EPAR findings related to fractures associated with these medications.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
I Farmaci Antidiabetici e la Fragilit Ossea Ilaria Dicembrini Diabetologia Azienda Ospedaliero-Universitaria Careggi
SGLT-2i Reduced tubular reabsorption of glucose
Canagliflozin and fractures FDA warning Pooled analysis of 9 clinical trials, mean follow-up 85 wk RCT, 2y, 714 pts Placebo-substracted % difference lumbar hip Incidence of bone fractures 1.5 1.4 1.1 -0.3 -0.7 -0.9 -1.2 100 300 100 300 mg Comp 300 100 FDA, 10 sept 2015.
Dapagliflozin and fractures EPAR for dapagliflozin Renal excretion of calcium and phosphate was not studied extensively in patients although this was a prominent effect in animals and may have contributed to the increased fracture rate observed with dapagliflozin use in renally impaired patients (particularly with eGFR < 45 ml/min/1.73 m2). www.ema.europa.eu
Dapagliflozin and bone Placebo-controlled RCT, add-on to metformin Dapagliflozin 10 mg, 50 wk, 73 women % difference from baseline Hip Femural neck +0.3 -0.3 -0.3 -0.8 Pbo Dapa Pbo Dapa Ljunggren et al., Diabetes Obes Metab 14: 990 999, 2012.
Empagliflozin and fractures EMPA-REG OUTCOME trial Zinman et al., N Engl J Med 2015.
Diabetes treatment and skeletal outcome Summary of clinical studies
